



INVESTOR PRESENTATION

NASDAQ (OGI)
TSX (OGI)



Q3 Fiscal 2024

06 | 30 | 24

CAUTIONARY STATEMENT

This document is current as of June 30, 2024, except where otherwise stated. The information contained in this presentation is provided by Organigram Holdings Inc. ("Organigram" or the "Company") for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Organigram or other financial products. No part of this presentation shall form the basis or be relied upon in connection with any contract, commitment or investment decisions in relation thereto. The information contained herein is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. No securities commission or similar regulatory authority in Canada or the United States has reviewed this presentation.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. This presentation is not meant to provide a complete or comprehensive analysis of Organigram's financial or business prospects. To the maximum extent permitted by law, none of Organigram nor its directors, officers, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this presentation.

This presentation contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "estimates", "intends", "anticipates", "believes" or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, including but not limited to the anticipated closing of the subsequent tranches of the follow-on investment from the subsidiary of BAT. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this presentation, including risk of failure to close any transactions within the timeline expected, or at all, for any reasons. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-

looking information include factors and risks as disclosed in the Company's most recent annual information form, management's discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this presentation are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this presentation is made as of the date of this presentation and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The descriptions of the terms of the agreements referenced in this release are qualified by the terms of the agreements themselves, copies of which shall be filed under Organigram's profile on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov).

The financial information in this document contains certain financial performance measures that are not defined by and do not have any standardized meaning under IFRS and are used by management to assess the financial and operational performance of the Company. These include adjusted EBITDA and adjusted gross margin (adjusted gross margin %). The Company believes that these non-IFRS financial measures, in addition to conventional measures prepared in accordance with IFRS, enable investors to evaluate the Company's operating results, underlying performance and prospects in a similar manner to the Company's management. As there are no standardized methods of calculating these non-IFRS measures, the Company's approach may differ from those used by other issuers, and accordingly, the use of these measures may not be directly comparable. Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. For further information regarding these non-IFRS measures, including definitions, and a quantitative reconciliation to the most directly comparable IFRS measure, see the

information under the heading "Cautionary Statement Regarding Certain Non-IFRS Measures" and the reconciliation to IFRS measures under the heading "Financial Results and Review of Operations" in the Company's management discussion and analysis of financial conditions and results of operations for the three months ended June 30, 2024 and May 31, 2023 (the "Q3 Fiscal 2024 MD&A") incorporated by reference in this presentation and filed under Organigram's profile of SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov).

This presentation does not constitute an offer of shares for sale in the United States or to any person that is, or is acting for the account or benefit of, any U.S. person as defined in Regulation S under the United States Securities Act of 1933, as amended (the "Securities Act"), or in any other jurisdiction in which such an offer would be illegal. Organigram's shares have not been and will not be registered under the Securities Act. We seek safe harbour. This document may not be reproduced, further distributed or published in whole or in part by any other person. This document may only be disseminated or transmitted into any jurisdiction in compliance with, and subject to, applicable securities laws. Readers are required to ensure their compliance with applicable securities laws.

This investor presentation contains information concerning our industry and the markets in which we operate, including our market position and market share, which is based on information from independent third-party sources. Although we believe these sources to be generally reliable, market and industry data is inherently imprecise, subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process, and other limitations and uncertainties inherent in any statistical survey or data collection process. We have not independently verified any third-party information contained herein.

All dollar values are in Canadian dollars unless otherwise indicated.



ORGANIGRAM



AN AWARD-WINNING CANNABIS LICENSED PRODUCER WITH A PRESENCE ACROSS CANADA AND A GROWING INTERNATIONAL FOOTPRINT



Our Vision:

To be a respected global leader in the emerging cannabis movement.



Our Mission:

To delight consumers with trusted brands that deliver innovative cannabis products and experiences while promoting education and industry advocacy.

KING
magazine



**MOST INNOVATIVE
PRODUCT OF THE YEAR**

**EDISON
JOLTS**



ORGANIGRAM

Licensed Producer
of the Year 2022

KING
magazine



WINNER
KING Innovation
of the Year Award!

© Organigram Inc.

ORGANIGRAM KEY STRENGTHS



One of the strongest balance sheets among LPs

Negligible debt & ~\$173 million in pro-forma cash¹



Three state-of-the-art specialized facilities & the largest indoor grow in Canada



Distribution spans all Canadian provinces with seven international export partners in Germany, UK, Israel, & Australia

US exposure through two strategic investments

EU exposure through ~\$21 million investment in German cannabis leader, Sanity Group GmbH ("Sanity Group")



Innovation focus with several first-to-market launches including milled flower, Rip-Strip hash, whole-flower THCV, & ingestible extracts

Recently announced FAST™ Nanoemulsion technology for ingestible products



Consistently a top 3 LP in national market share²

Top 3 in multiple product categories²

A LEADER IN PRODUCT INNOVATION

Organigram is focused on innovation informed by consumer research, resulting in market share leadership in several categories



- Revolutionized hash with patent-pending SHRED X Rip-Strips
- SHRED brand has achieved \$200 million in annual retail sales¹
- First to market with ingestible extracts and flavour forward milled flower
- Introduced whole-flower derived THCv products to the Canadian consumer
- Expanding in vapes with new all-in-one hardware
- Launched the Company's first carton of joints in market - 7 packs of 10 tube-style PRs
- Planning launch of Nanoemulsion ingestibles with clinically studied effects to substantiate claims of rapid onset and greater bioavailability in fall 2024



FOCUSED ON GLOBAL EXPANSION & EFFICIENCY

Organigram has completed significant efficiency-driving capex projects and is deploying capital to establish a larger global presence

- Capital raised in Fiscal 2024:
 - \$124.6 million follow-on investment from BAT to fund international and strategic growth initiatives¹
 - \$28 million oversubscribed underwritten offering announced in March 2024 and closed in April 2024 to fund growth initiatives and for general corporate purposes
- Current export partners in Australia, Germany, Israel, & UK (\$18.9 million in international shipments in Fiscal 2023 to Israel and Australia)
- EU-GMP preliminary audit of Moncton facility successful and awaiting official audit expected in calendar 2024
- Organigram has US exposure through two strategic investments in Phyllos Bioscience Inc. ("Phyllos") and Steady State LLC (d/b/a Open Book Extracts)("OBX")
- In June 2024, Organigram announced a ~\$21 million investment in Sanity Group to establish a foothold in the European market




EFFICIENCY



EXPANSION

ORGANIGRAM'S GLOBAL FOOTPRINT



BAT INVESTMENTS IN ORGANIGRAM

Product Development Collaboration

March 2021 - \$221 million strategic investment from subsidiary of BAT for 19.9% equity interest¹ in Organigram

- Product Development Collaboration ("PDC") with formation of a Center of Excellence ("CoE") at our Moncton campus
- Focused on developing the next generation of cannabis products, IP and technologies

Jupiter Strategic Investment Pool

November 2023 - Up to \$124.6 million follow-on investment from subsidiary of BAT in three equal tranches between January 2024 and February 2025 for:

- 45.0% economic interest in private placement at \$3.22 per share²
- Organigram to create a strategic investment pool named Jupiter, to be funded with \$83.1 million over the course of the three tranches of the investment
- Jupiter will target investments in emerging cannabis opportunities that enable Organigram to apply industry-leading capabilities to new markets
- \$41.5 million proceeds for general corporate purposes
- First \$41.5 million tranche closed in January 2024
- Second \$41.5 million tranche expected to close in August 2024



1. Calculated on a non-diluted basis.

2. On the last trading day pre-announcement (November 3, 2023) of the transaction, Organigram shares closed at C\$1.59/share on the Toronto Stock Exchange.

PRODUCT DEVELOPMENT COLLABORATION

FAST™ Nanoemulsion technology for ingestible products is the first patent-pending innovation to be commercialized leveraging the output of the PDC in fall 2024

Innovation Highlights

- Organigram has unveiled preliminary results of what is believed to be the largest pharmacokinetic (PK) study focused on adult-use cannabis products. The results of the study have given early indications of technological advances, including but not limited to:
 1. Faster onset compared to traditional ingestible products from the control group. Depending on ingestible format, up to approximately 50% faster onset of the effects of cannabis was observed.
 2. Improved bioavailability of cannabinoids: up to double the cannabinoid delivery at peak compared to the control group.
 3. Early indicators of a more predictable duration of the effects of cannabis showing promising signals for the development of future offset claims, subject to additional supporting studies.
- Full scale-up manufacturing runs for Nanoemulsion gummies have been completed at Organigram's Winnipeg facility, with the gummies expected to launch in fall of 2024
- The PDC continues to focus on the development of next generation products, adhering to the highest regulatory and compliance standards.



JUPITER INVESTMENT POOL

The \$83 million Jupiter investment pool targets investments in emerging cannabis opportunities

- All potential investments are made in alignment with Organigram's strategic vision for the future, focusing on long-term sustainable growth and global cannabis leadership
- Targeting investments that will enable Organigram to apply its industry-leading capabilities to new markets
- Jupiter is managed by an internal team at Organigram
- Internal team is focused on sourcing future investments, enabling both an entrepreneurial approach and application of best-in-class knowledge
- All investments go through legal due diligence, ensuring compliance with both applicable laws and Organigram's listings on the NASDAQ & TSX
- Jupiter has deployed capital to two strategic targets: US\$2 million in Open Book Extracts, and ~\$21 million interest in Sanity Group



DOMESTIC & INTERNATIONAL PERFORMANCE

Organigram continues to grow domestic market share in key categories and over-indexes in international sales as a proportion of Canadian exports:


Canada

- #3 market share position in Canada¹
- #1 market share in milled flower and hash¹
- #3 market share in gummies¹
- #3 in rapidly growing pre-roll category after recent highly successful launches of tube-style pre-rolls and diamond + distillate infused-pre-rolls¹
- #1 market share in Atlantic Canada, and #3 in Ontario and a top 5 LP in every other province¹



Rest of World

- In Fiscal 2023 Organigram shipped an estimated 10% of all exported product from Canada² to international markets (including Israel and Australia)
- New supply agreements signed with Sanity Group in Germany and 4C Labs Ltd. in the UK expected to bolster international sales in Fiscal 2024 – First flower shipped to Germany in Q1 Fiscal 2024. First sales destined for UK in Q4 Fiscal 2024
- In June 2024, Organigram established a foothold in the EU market through its \$21 million investment into Sanity Group, a German cannabis leader



STATE OF THE ART FACILITIES

Organigram's legacy of execution excellence & stability is established in the Canadian market, supported by three fully-scaled, state-of-the-art facilities:

Moncton (Flagship)

- One of the largest indoor cannabis facilities in the world
- >85,000 kg/year of low-cost, high-quality indoor flower
- Three-tiered, modular, strain-specific grow rooms provide the ability to control critical environmental requirements per strain
- In-house extraction, cannabinoid testing, and remediation
- Expecting near-term audit for EU-GMP certification

Winnipeg

- 51,000 sq. ft. edibles facility with automated cutting-edge equipment capable of producing up to 4 million gummies monthly
- Designed to produce nutraceutical-grade cannabis edibles
- Ramping up to produce Nanoemulsion ingestible products with potential rapid onset and predictable duration

Lac-Supérieur

- Producing hang-dried, hand-trimmed, artisanal craft cannabis
- Produce multiple hash products and patent-pending Rip-Strip Hash
- Hash production capacity of 2 million units per year
- 2,400kg/year of premium flower capacity













BRAND PORTFOLIO



WELL-ROUNDED BRAND PORTFOLIO

Recently hit \$200 million in annual retail sales

								
Pricing Segment 	Super Value	Value	Value	Mainstream	Mainstream	Mainstream	Premium	Craft
Available / Planned Formats 	Whole Flower	Whole Flower Pressed Hash	Pre-Milled Flower, Pre-Roll Joints, Infused Gummies, 510 Vape Carts, Rip-Strip Hash & Infused Pre-Rolls	CBD & Minor Cannabinoid Gummies	Pre-Rolls, Whole Flower, Infused Pre-Rolls, THC & Minor Cannabinoid Gummies	Whole Flower, Pre-Roll Joints & Lozenges	Hashish, Hash Infused Pre-rolls & Pre-rolls	Whole Flower Pre-Roll Joints
Tangible Brand Attributes 	Strain Specific Flower High Quality Genetics Good value	Iconic Strains High Potency Products Killer Prices	Good THC Potency Great Value Big Flavour	Assorted Flavours Vegan & Sugar-free Offerings	Assorted Flavours Vegan & Sugar-free Offerings	Potent & Flavourful Strains Unparalleled Genetics Strain Specific Grow Rooms	Authentic Recipes High Potency Hash	Hand Trimmed Hand Packed Hang Dried

DYNAMIC BRAND PERFORMANCE



The #1 LP in Hash¹

- Organigram holds 20% of national market share in hash¹
- Innovative Rip-Strip Hash Launched in March 2023 - over 450K units shipped approaching \$14 million in retail sales as of June 30, 2024¹



CBD Market Share Leader

- The best-selling CBD gummy brand in Canada¹
- Robust portfolio focusing on an array of minor cannabinoids like CBD, CBG, THCV, and CBN



Top 3 LP in Pre-Rolls¹

- Grew to over 16% market share of tube-style pre-rolls appx. 1-year after launch in August 2023¹
- 6.4% market share in all pre-rolls, up 100% in Q3 Fiscal 24 vs Q3 Fiscal 23¹



STRATEGIC INVESTMENTS



ESTABLISHED FOOTHOLD IN EUROPEAN MARKET

- In June 2024, Organigram made its second Jupiter investment into Germany-based Sanity Group, agreeing to invest ~\$21 million
- Concurrent to the investment, Organigram and Sanity Group have entered into a new supply agreement to include significantly higher volumes and the intention to work together on the commercialization of Organigram's brands and intellectual property (IP) in Germany
- Sanity Group is a leader in the German cannabis market
- Once Organigram receives EU-GMP certification in Moncton, Sanity Group will shift its annual purchase commitment from Organigram to a percentage of its overall assortment of flower offerings for the European market. Organigram expects to complete its final EU-GMP audit before the end of the calendar year
- Sanity is currently participating in a Swiss recreational cannabis pilot program, with two stores operational and a plan to expand its retail footprint in Switzerland

avaay
MEDICAL

 Vayamed

 JUPITER

 ORGANIGRAM
 Sanity Group




INVESTMENT IN US HEMP-DERIVED CANNABINOIDS

- In March 2024, Organigram made its first Jupiter investment into US-based OBX as a convertible note for US\$2 million
- The investment in OBX provides a further footprint in the U.S, which was a strategic priority set out in the Jupiter investment strategy
- Through its investment in OBX, Organigram will gain valuable insights into the U.S. market and its consumers. In time, Organigram plans to work with OBX to explore potential product launches in the U.S
- OBX and Organigram are currently discussing an opportunity for OBX to serve as a collaborative research partner for efficacy testing and formulation sciences
- OBX is nearing completion of its EU GMP certification, which will create further international collaboration opportunities between OBX and Organigram



INVESTMENT IN SEED GENETICS & THCV

- In May of 2023, Organigram made its first investment into the U.S cannabis market by issuing a strategic convertible loan of up to US \$8 million to Phylos in three tranches
- Phylos has enabled Organigram to launch of products containing whole-flower THCV
- Organigram will significantly reduce operating costs by transitioning its flower production from cloning to seed which reduces the need for cloning, propagation, and pre-vegetation
- In Q1 Fiscal 2024, Organigram advanced the second tranche of US\$2.75 million to Phylos for a total current investment of US\$6.0 million in senior secured convertible loans
- First three seed-based room harvested in Q3 Fiscal 2024 with four additional rooms harvested in July 2024, moving toward goal of approximately 30% seed-based production by end of calendar 2024
- In July 2024, Organigram advanced US\$1 million of the final US\$2 million investment tranche to Phylos with the remaining portion to be funded upon completion of newly expanded milestones




phylos




INVESTMENT IN DISRUPTIVE VAPING TECHNOLOGY

- In March of 2023, Organigram invested \$5.5 million into Green Tank Technologies Corp. ("Greentank"), a vape R&D firm and hardware manufacturer
- Greentank's heating technology is the first meaningful innovation in the vape space in almost a decade
- More consistent flavour, reduce clogging and produce smaller particle size which may increase potency
- 18-month exclusivity period
- Test launch completed in Q2 Fiscal 2024. Full market launch of all-in-one device expected in Q1 Fiscal 2025



INVESTMENT IN BIOSYNTHESIS

- 49% ownership (if convertible debt converted) of Hyasynth Biologicals Inc., a pioneer in cannabinoid science
- Biosynthesis process uses patent-pending yeast strains and enzymes to produce pure cannabinoids (not synthetic) without growing cannabis plants
- Potential to create a scalable supply of pure cannabinoids at a fraction of the cost and time of traditional cultivation using smaller environmental footprint



How it works?

Biosynthesis can be used to produce cannabinoids that are identical to those produced by the plant itself.



Genome engineering of yeast: A group of genes for cannabinoid production are added to the yeast genome of a yeast strain, where it provides instructions to produce cannabinoid compounds.

Yeast fermentation and purification:
New yeast strains are grown in fermentation over a few days and pure cannabinoids are extracted at the end of the process.



The process is conducted at large scale, resulting in pure cannabinoids that can be used as ingredients in other products.



QUARTERLY UPDATES & HIGHLIGHTS



Q3 F2024

A LEADING CANADIAN LP

- Organigram held the #3 national market share position¹
- Held the #1 position in milled flower, the #1 position in hash, the #3 position in gummies, the #3 position in infused pre-rolls, and the #3 position in pre-rolls nationally¹
- Organigram is a top 3 LP in Canada in every major product category, apart from vapes¹
- #1 in LP in Atlantic Canada, #3 in Ontario, and held top 5 market position in rest of Canada¹

1. As of June 30, 2024 – Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling).




Q3 F2024 HIGHLIGHTS

- Net revenue of \$41.1 million increased 25% over the prior year period
- Positive adjusted EBITDA¹ of \$3.5 million up from \$(2.9) million in prior year period
- Established European foothold with \$21 million strategic investment in Sanity Group, a leading German cannabis company
- Completed landmark clinical study on FAST™ Nanoemulsion technology showing faster onset and improved bioavailability of ingestible products
- Continued global expansion by signing two new supply agreements with clients in Australia and the UK
- Pro-forma cash position of \$173 million²




QUARTERLY REVENUE

REVENUE
\$ millions



ADJUSTED GROSS MARGIN

ADJUSTED GROSS MARGIN¹
\$ millions and % of Net Revenue



1. Adjusted gross margin is a non-IFRS financial measure not defined under IFRS and which does not have any standardized meaning under IFRS and might not be comparable to similar financial measures disclosed by other issuers; please refer to the cautionary statement at the beginning of this document and the Company's Q3 Fiscal 2024 MD&A for definitions and a reconciliation to IFRS

ADJUSTED EBITDA

ADJUSTED
EBITDA¹
\$ millions



1. Adjusted EBITDA is a non-IFRS Financial Measure not defined by and does not have any standardized meaning under IFRS and might not be comparable to similar financial measures disclosed by other issuers; please refer to the cautionary statement at the beginning of this document and the Company's Q3 Fiscal 2024 MD&A for definitions and a reconciliation to IFRS.

2. Q4 F2023 represents 4 months due to a change in Organigram's year end. Adjusted EBITDA here has been normalized to reflect a 3-month period.

STRONG BALANCE SHEET AND LIQUIDITY

- On June 30, 2024, the Company had cash of **\$89.5 million** (including restricted cash)
- In April 2024, the Company closed a financing for gross proceeds of **\$28.8 million**
- **Pro-forma cash position of ~\$173 million** upon the anticipated closure of the final BAT tranche
- **Negligible debt** (less than \$0.2 million)



Q3 FISCAL 2024 KEY FINANCIAL METRICS

*In \$ millions unless
otherwise indicated*

	Q3'24	Q3'23	% Change
Gross revenue	63,605	48,409	31%
Excise taxes	(22,545)	(15,624)	44%
Net revenue	41,060	32,785	25%
Cost of sales	27,173	32,289	(16)%
Gross margin before fair value changes to biological assets & inventories sold	13,887	496	2700%
Realized fair value on inventories sold and other inventory charges	(13,728)	(13,588)	1%
Unrealized gain on changes in fair value of biological assets	13,849	8,395	65%
Gross margin	14,008	(4,697)	nm
Adjusted gross margin ¹	14,586	6,074	140%
Adjusted gross margin % ¹	36%	19%	17%
Selling (including marketing), general & administrative expenses	14,797	19,033	(22)%
Adjusted EBITDA ¹	3,465	(213,451)	nm
Net income (loss)	2,818	(2,914)	nm
Net cash provided by (used in) operating activities	(182)	(14,847)	(99)%

1. Adjusted gross margin, adjusted gross margin % and adjusted EBITDA are non-IFRS financial measures not defined by and do not have any standardized meaning under IFRS and might not be comparable to similar financial measures disclosed by other issuers; please refer to the cautionary statement at the beginning of this document and the Company's Q3 Fiscal 2024 MD&A for definitions and a reconciliation to IFRS.



APPENDIX



MARCH 2021 BAT TRANSACTION SUMMARY

<p>Investment</p>	<ul style="list-style-type: none"> Subsidiary of BAT subscribed for 58.3M common shares of Organigram, which represented a 19.9% equity interest in March 2021¹ on a post-transaction basis <ul style="list-style-type: none"> Total proceeds to Organigram in March 2021 of ~\$221 million (the “Investment Proceeds”) The price per share in March 2021 was based on a five-day volume weighted average price on the TSX ended March 9, 2021 In March 2022 received \$6.3M investment from BAT through the exercise of certain top-up rights pursuant to an Investor Rights Agreement, bringing BAT’s equity ownership to 19.4%
<p>Product Development Collaboration (“PDC”)</p>	<ul style="list-style-type: none"> ~\$30M of Investment Proceeds reserved to satisfy certain of Organigram’s obligations under the PDC agreement, including Organigram’s portion of its funding obligations under a mutually agreed budget for the CoE <ul style="list-style-type: none"> Remaining net Investment Proceeds may be used by Organigram for general corporate purposes, subject to certain proceed restrictions Costs relating to the CoE are funded equally by OGI and BAT Organigram and BAT to focus on development of cannabis vapour products, cannabis oral products and any other products, IP and technologies mutually agreed upon Both Organigram and BAT to have access to certain of each other’s intellectual property and, subject to certain limitations, have the right to independently globally commercialize the products, technologies and IP
<p>Governance and Deal Protections</p>	<ul style="list-style-type: none"> Board Representation: <ul style="list-style-type: none"> BAT entitled to appoint (i) 20% of the Board of Directors of Organigram (the “Board”) for so long as BAT holds at least 15% of the issued and outstanding common shares of Organigram from time to time and (ii) 10% of the Board so long as BAT holds at least 10% of the issued and outstanding common shares of Organigram from time to time Investor Rights <ul style="list-style-type: none"> BAT has a right to participate in equity issuances to maintain its percentage shareholding, subject to customary exceptions, and periodic top-up rights to permit maintenance of its percentage ownership following exempt issuances BAT has customary pro rata piggy-back registration rights, and is subject to certain share transfer restrictions

1. Calculated on a non-diluted basis.

NOVEMBER 2023 BAT TRANSACTION SUMMARY

Investment	<ul style="list-style-type: none">• Subject to requisite Organigram shareholder approval, regulatory approvals and other conditions, subsidiary of BAT to subscribe for, in aggregate, ~38.7 million shares of Organigram, over three tranches, at \$3.2203/share.• Total gross proceeds to Organigram of C\$124.6 million• Subsidiary of BAT, subject to Organigram shareholder approval, regulatory approvals and other conditions, will subscribe for:<ul style="list-style-type: none">• Tranche 1 - ~12.9 million shares closed on January 24, 2024, for \$41.5 million• Tranche 2 - ~12.9 million shares on or around August 30, 2024, for \$41.5 million• Tranche 3 - ~12.9 million shares on or around February 28,2025, for \$41.5 million
Capital Allocation and “Jupiter” Investment Pool	<ul style="list-style-type: none">• Organigram to create a strategic investment pool named Jupiter, to be funded with \$83.1 million over the course of the three tranches of the investment• Remaining net Investment Proceeds of C\$41.5 million may be used by Organigram for general corporate purposes• Jupiter will target investments in emerging cannabis opportunities that enable Organigram to apply industry-leading capabilities to new markets, thus expanding its global footprint• Jupiter to be set-up and managed by an internal team at Organigram
Governance and Deal Protections	<ul style="list-style-type: none">• Board Representation:<ul style="list-style-type: none">• Under the Amended and Restated IRA, BAT would be eligible to appoint up to 30% of the Board.• BAT nominees, Mr. Simon Ashton was added to the Board in February 2022 and Ms. Ferland was added to the Board in March 2023 but subsequently resigned in September 2023. Karina Gehring was added to the Board in January 2024, and Craig Harris was added to the Board in July 2024 æ BAT’s second and third nominees, respectively.• Investor Rights:<ul style="list-style-type: none">• BAT has a right to participate in equity issuances to maintain its percentage shareholding, subject to customary exceptions, and periodic top-up rights to permit maintenance of its percentage ownership following exempt issuances.• BAT has customary pro rata piggy-back registration rights and is subject to certain share transfer restrictions.• BAT has certain minority protections, including approval rights over certain fundamental transactions.

SHRED

An uplifting & vibrant value brand
focused on convenience.



Tropic Thunder 7g pre-milled
Wild Berry Blaze SHRED'ems
Gnarberry 1g 510 vape
SHRED X Rip Strips

HOLY MOUNTAIN

An imaginative brand with iconic strains and stellar extracts.



Holy Mountain

Mac-1 3.5 g, R*ntz 3.5g, Pressed Hash

BIG BAG O' BUDS

Delivering high-quality ounces in a variety of strains.



Pink Cookies
I.C.C.
Ultra Sour



CBD and minor cannabinoid gummies,
designed for a personal wellness ritual.



Monjour Berry Good Day
Monjour Orchard Medley



A premium brand focused on
flower & innovation.



Limelight 3.5g dried flower
Edison JOLTS – Electric Lemon
Cherry Limelight Bubble Hash Joints



TREMBLANT

THE ART OF HASH
L'ART DU HASCHISH

Premium hash, inspired by
the timeless tradition of hashish.





Craft cannabis featuring rare cultivars grown with utmost attention and care.



Laurentian Saisons
3.5 g

Trailblazer

Craft cannabis featuring rare cultivars grown with utmost attention and care.



Q3 FISCAL 2024 SELECT BALANCE SHEET METRICS

*In \$000s unless
otherwise indicated*

SELECT BALANCE SHEET METRICS	June 30, 2024	September 30, 2023	% Change
Cash & short-term investments (excluding restricted cash)	80,067	33,864	114%
Biological assets & inventories	84,079	80,953	3%
Restricted Cash	9,440	17,893	(38%)
Other current assets	41,506	41,159	(7%)
Accounts payable & accrued liabilities	39,722	20,007	101%
Current portion of long-term debt	61	76	(13%)
Working capital	163,851	133,545	4%
Property, plant & equipment	95,435	99,046	(2%)
Long-term debt	39	79	(34%)
Total assets	354,748	298,455	11%
Total liabilities	58,892	26,832	124%
Shareholders' equity	295,856	271,623	nm

Q3 FISCAL 2024 CAPITAL STRUCTURE

in \$000s	June 30, 2024	Sept 30, 2023
Current and long-term debt	100	155
Shareholders' equity	295,856	271,623
Total debt and shareholders' equity	295,956	271,778
in 000s		
Outstanding common shares	103,801	81,162
Options	2,810	2,830
Warrants	4,451	4,236
Top-up rights	7,139	2,035
Restricted share units	3,342	881
Performance share units	1,124	261
Total fully-diluted shares	122,667	91,405



 ORGANIGRAM



A CANADIAN CANNABIS LEADER

NASDAQ (OGI)
TSX (OGI)